SNDX Q3 2025 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+267.0% YoY

Gross Profit

$39M86.1% margin

Operating Income

-$57M-125.2% margin

Net Income

-$61M-132.4% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+20.8%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$71M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$552M

Total Liabilities

$436M

Stockholders' Equity

$115M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$13M	+267.0%
Gross Profit	$39M	$13M	+215.9%
Operating Income	-$57M	-$90M	+35.9%
Net Income	-$61M	-$84M	+27.8%

Revenue Segments

Product

$32M70%

Collaboration revenue

$14M30%